3-(benzyloxy)picolinic acid | 117523-29-2

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-(benzyloxy)picolinic acid
• 英文别名: 3-(benzyloxy)pyridine-2-carboxylic acid；3-Benzoyl-picolinsaeure；3-Benzyloxy-picolinsaeure；3-phenylmethoxypyridine-2-carboxylic acid
• CAS: 117523-29-2
• 化学式: C₁₃H₁₁NO₃
• 分子量: 229.235
• InChiKey: MWHFMAMJIYHCLW-UHFFFAOYSA-N

物化性质

• 沸点：
  423.8±30.0 °C(Predicted)
• 密度：
  1.274±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  59.4
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  3-(benzyloxy)picolinic acid 在 草酰氯 、 TEA 作用下， 以 二氯甲烷 为溶剂， 生成 3-Benzyloxy-pyridine-2-carboxylic acid thiazol-2-ylamide
  参考文献：
  名称：

  Inhibitors of type I MetAPs containing pyridine-2-carboxylic acid thiazol-2-ylamide. Part 1: SAR studies on the determination of the key scaffold

  摘要：

  Systematic SAR studies on the HTS hit pyridine-2-carboxylic acid thiazol-2-ylamide (PACT) analogues revealed that the scaffold of OCAT is indispensable for the inhibition of type I MetAP. For effective inhibition of the enzyme, the most suitable position to modify is the 3-position of the pyridine ring of PCAT, and the best substituents are those containing O or N atoms connected directly with the pyridine ring. These findings provide useful information for the design and discovery of more potent inhibitors of type I MetAPs. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.11.034
• 作为产物：
  描述：

  3-羟基-2-吡啶甲酸 在 lithium hydroxide 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 3-(benzyloxy)picolinic acid
  参考文献：
  名称：

  Synthesis of key sandramycin analogs: systematic examination of the intercalation chromophore

  摘要：

  The preparation and examination of 2-22 constituting a systematic study of the chromophore of sandramycin (1) are detailed. Fluorescence quenching studies were used to establish binding constants for 1-24 within calf thymus DNA, within a single high affinity bis-intercalation binding site 5'-d(GCATGC)(2), and to establish the preference for sandramycin binding to 5'-d(GCXXGC)(2) where XX = AT, TA, GC, and CG. From the latter studies, sandramycin was found to exhibit a preference that follows the order: 5'-d(GCATGC)(2) > 5'-d(GCGCGC)(2), Delta Delta G degrees = 0.3 kcal/mol > 5'-d(GCTAGC)(2), 5'-d(GCCGGC)(2), Delta Delta G degrees = 0.6 kcal/mol although it binds with high affinity to all four deoxyoligonucleotides. The two highest affinity sequences constitute repeating 5'-PuPy motifs with each intercalation event occurring at a 5'-PyPu step. The most effective sequence constitutes the less stable duplex, contains the sterically most accessible minor groove central to the bis-intercalation site, and the ability to accept two gly-NH/T C2 carbonyl H-bonds identified in prior NMR studies. Similarly, the contribution of the individual structural features of the chromophore were assessed with the high affinity duplex sequence 5'-d(GCATGC)(2). To a first approximation, the cytotoxic properties were found to parallel trends established in the DNA binding affinities. The exception to this generalization was 4 which lacks the sandramycin chromophore phenol. Although typically 4-10x less potent than sandramycin against leukemia cell lines, it proved to be 1-10,000x more potent against melanomas, carcinomas, and adenocarcinomas exhibiting IC50 values of IpM-10 nM placing it among the most potent agents identified to date. Additionally, the first disclosure of the HIV-1 reverse transcriptase inhibitory activity of sandramycin (1) as well as that of its key analogs are described and define the chromophore structural features required for their exceptional potency. Two analogs, 18 and 3, roughly maintain the HIV-I reverse transcriptase inhibitory potency of 1 but exhibit substantially diminished cytotoxic activity (10(2) - 10(3)x). (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(97)10014-1

文献信息

• [EN] PIPERIDINE AMIDES AS MODULATORS OF THE GHRELIN RECEPTOR<br/>[FR] PIPÉRIDINE-AMIDES EN TANT QUE MODULATEURS DU RÉCEPTEUR DE LA GHRÉLINE
  申请人：PROSIDION LTD

  公开号：WO2011117254A1

  公开（公告）日：2011-09-29

  Compounds of formula (I) or pharmaceutically acceptable salts thereof, are useful for the treatment of diabetes and obesity.

  化合物的结构式（I）或其药学上可接受的盐，可用于治疗糖尿病和肥胖。
• Substituted heterocyclic carboxamide esters, their preparation and their
  申请人：Hoechst Aktiengesellschaft

  公开号：US05658933A1

  公开（公告）日：1997-08-19

  The invention relates to compounds of the formula I, ##STR1## to a process for their preparation and to their use as pharmaceuticals. The compounds are employed, in particular, as ester prodrugs of prolyl hydroxylase inhibitors for inhibiting collagen biosynthesis and as fibrosuppressive agents.

  这项发明涉及公式I的化合物，用于它们的制备过程以及作为药物的用途。这些化合物特别用作脯氨酸羟化酶抑制剂的酯前药，用于抑制胶原蛋白的生物合成，并作为抗纤维增生剂。
• Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
  申请人：HOECHST AKTIENGESELLSCHAFT

  公开号：EP0650960A1

  公开（公告）日：1995-05-03

  Die Erfindung betrifft Verbindungen der Formel I, ein Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel. Insbesondere werden die Verbindungen als Ester-Prodrugs von Prolylhydroxylase-Inhibitoren eingesetzt zur Hemmung der Kollagenbiosynthese, und als Fibrosuppressiva.

  本发明涉及式 I 的化合物、 的制备工艺及其作为药物的用途。特别是，这些化合物可用作脯氨酰羟化酶抑制剂的酯原药，以抑制胶原蛋白的生物合成，还可用作纤维抑制剂。
• PICOLINAMIDE DERIVATIVES AND PEST CONTROLLERS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
  申请人：Meiji Seika Kaisha, Ltd.

  公开号：EP1134214A1

  公开（公告）日：2001-09-19

  Disclosed are novel compounds useful for the control of harmful organisms, harmful organism control agents using the same, and processes for producing the novel compounds. The useful novel compounds according to the present invention include compounds represented by formula (1). The compounds represented by formula (1) have potent activity against harmful organisms, and do not have phytotoxicity against agricultural and gardening plants, as objects to which the compounds of the present invention are applied for preventive and exterminating purposes, and human beings and beasts. wherein A represents a bond or an optionally substituted alkylene chain; R1 represents one or more groups, which may be the same or different, selected from the group consisting of a hydrogen atom, alkoxy, and haloalkoxy; R2 represents a hydrogen atom, benzyl, alkyl or alkanoyl, in which the groups other than the hydrogen atom may be substituted; and R3 represents a hydrogen atom, cycloalkyl, cycloalkenyl, aryl or a heterocyclic group, in which the groups other than the hydrogen atom may be substituted, excluding the case where R1 represents a hydrogen atom, A represents a bond or a methylene chain, and R3 represent phenyl or cyclohexyl, and the case where A represents an alkylene chain and R3 represents a hydrogen atom.

  本发明公开了用于控制有害生物的新型化合物、使用这些化合物的有害生物控制剂以及生产这些新型化合物的工艺。根据本发明，有用的新型化合物包括由式（1）代表的化合物。式（1）代表的化合物对有害生物具有强效活性，并且对农业和园艺植物没有植物毒性，而农业和园艺植物是本发明化合物用于预防和消灭的对象，人类和野兽也是本发明化合物的对象。 其中 A 代表键或任选取代的亚烷基链；R1 代表一个或多个基团，它们可以相同或不同，选自由氢原子、烷氧基和卤代烷氧基组成的组；R2 代表氢原子、苄基、烷基或烷酰基，其中氢原子以外的基团可以被取代；以及 R3 代表氢原子、环烷基、环烯基、芳基或杂环基，其中氢原子以外的基团可被取代，但不包括 R1 代表氢原子、A 代表键或亚甲基链、R3 代表苯基或环己基的情况，以及 A 代表亚烷基链、R3 代表氢原子的情况。
• In Pursuit of Natural Product Leads: Synthesis and Biological Evaluation of 2-[3-hydroxy-2-[(3-hydroxypyridine-2-carbonyl)amino]phenyl]benzoxazole-4-carboxylic acid (A-33853) and Its Analogues: Discovery of <i>N</i>-(2-Benzoxazol-2-ylphenyl)benzamides as Novel Antileishmanial Chemotypes
  作者：Suresh K. Tipparaju、Sipak Joyasawal、Marco Pieroni、Marcel Kaiser、Reto Brun、Alan P. Kozikowski

  DOI：10.1021/jm801241n

  日期：2008.12.11

  The first synthesis and biological evaluation of antibiotic 31 (A-33853) and its analogues are reported. Initial screening for inhibition of L. donovani, T. b. rhodesiense, T cruzi, and P. falciparum cultures followed by determination of IC50 in L. donovani and cytotoxicity on L6 cells revealed 31 to be 3-fold more active than miltefosine, a known antileishmanial drug, Compounds 14, 15, and 25 selectively inhibited L. donovani at nanomolar concentrations and showed much lower cytotoxicity.